http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019290723-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9382680a2c549a7cdddfe11a21421a3d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
filingDate 2019-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edfb2b648351d761283df54903e68ca5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca26dc87f285e7604f39d8a0b387720c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edc93176bef003379dc12323798012d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09e32922ba156974c7c20f605467dd4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89907aa8e1b11e84c7723fba59c330c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9953eb1b376dd940e2cf51d510e1ad3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b52659bab63d6b296b085158226865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e90f8fe16d5352130772aec3d9e9c9
publicationDate 2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2019290723-A1
titleOfInvention High purity oritavancin and method of producing same
abstract Drug substance preparations of oritavancin having high purity are disclosed, along with pharmaceutical compositions comprising such oritavancin drug substance preparations, and drug products or dosage forms comprising such pharmaceutical compositions.
priorityDate 2014-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7427
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID592570
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID139518862
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID386878042
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16051955
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID158556840
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID139518860
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID386878044
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228168986
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14969
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID159467060
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22814120
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395424
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450711661
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449454343
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5651
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395422
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226446364

Total number of triples: 56.